Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Control of the immune responses is critical for body homeostasis. Immunosuppressive strategies have been critical to this enterprise as they reveal molecular and cellular mechanisms of immune-mediated tissue destruction. AREAS COVERED: While exerting potent effects to blockade critical processes during cell maturation prior to division and effector functions, the novel drug class of mammalian target of rapamycin inhibitors (mTORi) consequently exert adverse reactions due to disruption of pleiotropic physiologic pathways. This review includes selected clinical and preclinical materials from the time of the author's own first-in-human experience in 1993 through to 2009. The goal of this contribution is to provide a foundation in basic biochemical processes to allow the reader to understand the pathophysiology of adverse clinical reactions. EXPERT OPINION: mTORi, as potent agents for clinical immunosuppression, inevitably, disrupt multiple cellular pathways as well as important vectors of host resistance. Judicious use of this pharmacologic class demands dedication to learning strategies of individualization for patient needs and reactions in the manner of clinicians previously committed on the introduction of calcineurin inhibitors 3 decades ago.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study
Wilson, P. W. F. (1994) · JAMA · doi:10.1001/jama.1994.03520210050031 · Cited by 468
Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m100392-jlr200 · Cited by 295 · cited 1×
“1 Dyslipidemias The most prominent set of adverse reactions are hyperlipidemias [57], which occur in 60 -- 80% of mTORi-treated transplant recipients (Table 1).”
BackgroundSelf-citationThe Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man
Krebs, M., Brunmair, B., Brehm, A., Artwohl, M., Szendroedi, J., Nowotny, P., Roth, E., Fürnsinn, C., Promintzer, M., Anderwald, C., et al. (2007) · Diabetes · doi:10.2337/db06-1016 · Cited by 230
Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.014 · Cited by 80
Cited by
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Zhao, Y., Zhang, Z., Qin, S., Fan, W., Li, W., Liu, J., Wang, S., Xu, Z., & Zhao, M. (2021) · Neural Plasticity · doi:10.1155/2021/9926445 · Cited by 68
Signal Transduction Pathways of Acupuncture for Treating Some Nervous System Diseases.
Lai, H.-C., Chang, Q.-Y., & Hsieh, C.-L. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2909632 · Cited by 55
Manecka, D.-L., Vanderperre, B., Fon, E. A., & Durcan, T. M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00311 · Cited by 21
“The mTOR inhibitor rapamycin activates macroautophagy, prevents α-syn accumulation and aggregation, and ameliorates motor symptoms, but adverse effects have been reported (Kahan, 2011; Li et al., 2014; Tian et al., 2016).”
Background
Metadata
- Authors
- Kahan, B.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2011-05-11
- Volume
- 10
- Issue
- 5
- Pages
- 727-749
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2029594694
- Cited by
- 19
- References
- 4
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. https://app.cochat.ai/papers/10.1517/14740338.2011.579898
- The paper
- Kahan, B. (2011). Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2011.579898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.